Studies have suggested that although DM may augment systemic inflammation in patients with active TB, it attenuates mycobacteria-induced immune responses in those with LTBI by diminishing CD4-positive lymphocytes [8] and decreasing circulating levels of pro-inflammatory cytokines and anti-inflammatory cytokines [9]. This evidence concerns the gene CD4 and tuberculosis.